Stockscreener 앱 받기
37.77
0.03%
-0.010
전일 마감가:
$37.78
열려 있는:
$37.23
하루 거래량:
1.03M
Relative Volume:
0.47
시가총액:
$3.33B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-13.49
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
+10.25%
1개월 성능:
-11.79%
6개월 성능:
-21.79%
1년 성능:
-32.02%
1일 변동 폭
$37.23
$38.22
1주일 범위
$34.44
$40.13
52주 변동 폭
$30.04
$67.88
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
37.77 | 3.33B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
BofA Adjusts Price Target on CRISPR Therapeutics to $80 From $86, Keeps Buy Rating - MarketScreener
Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities - The Globe and Mail
BofA Adjusts Price Target for Crispr Therapeutics (CRSP) to $80 | CRSP Stock News - GuruFocus
Vanguard Group Inc. Acquires 10,579 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 4%Here's Why - MarketBeat
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week - Yahoo Finance
How To Trade (CRSP) - news.stocktradersdaily.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Holdings Lowered by Reynders McVeigh Capital Management LLC - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.11 Consensus Target Price from Analysts - MarketBeat
Gene Therapy Market Anticipated to Witness 20% CAGR Growth by 2029: Top Key Players like Novartis, Roche, CRISPR Therapeutics - PharmiWeb.com
CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
ExodusPoint Capital Management LP Acquires Shares of 47,840 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
California Public Employees Retirement System Sells 10,908 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Sets New 12-Month LowTime to Sell? - MarketBeat
LPL Financial LLC Buys 42,232 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Norges Bank Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics: Is This Biotech Surge Here to Stay? - timothysykes.com
First Week of May 30th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
Goldman Sachs maintains Neutral on CRISPR Therapeutics stock By Investing.com - Investing.com South Africa
Goldman Sachs maintains Neutral on CRISPR Therapeutics stock - Investing.com
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.11 Average Price Target from Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know - Yahoo Finance
Genome Editing Market Growth 2025: Trends, Consumer Demand, - openPR.com
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
Crispr Therapeutics AG: Strong Market Position and Financial Stability Justify Buy Rating - TipRanks
Is Vertex Pharmaceuticals Stock a Buy? - The Motley Fool
Layoff Tracker: Spark Lays Off 298 Employees - BioSpace
CRSP Stock Touches 52-Week Low at $30.8 Amidst Yearly Decline - Investing.com
Genome Engineering Market to Witness Remarkable Growth with - openPR.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - Yahoo Finance
Pictet Asset Management Holding SA Increases Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
16,100 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by KLP Kapitalforvaltning AS - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 8.7%What's Next? - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week LowTime to Sell? - MarketBeat
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 12% Weekly Dip Following COO Resignation - Yahoo Finance
Crispr Therapeutics gets orphan drug status for lymphoma treatment - Investing.com
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 1-Year LowTime to Sell? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 8.7%What's Next? - MarketBeat
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
크리스퍼 테라퓨틱스 주식 (CRSP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '25 |
Sale |
42.42 |
2,850 |
120,897 |
77,530 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 12 '25 |
Sale |
43.32 |
1,116 |
48,345 |
78,664 |
| Bruno Julianne | Chief Operating Officer |
Mar 11 '25 |
Sale |
42.42 |
1,198 |
50,819 |
8,263 |
| Bruno Julianne | Chief Operating Officer |
Mar 12 '25 |
Sale |
43.32 |
190 |
8,231 |
8,508 |
2.51%
자본화:
|
볼륨(24시간):